Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.65 |
| ▸ | EGFR | P00533 | 15/20 | 0.65 |
| ▸ | GAK | O14976 | 1/20 | 0.58 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3815330 | 0.93 | EGFR (0.65) | ERBB2EGFRGAKERBB3ERBB4 | |
| SCHEMBL3807511 | 0.92 | EGFR (0.66) | ERBB2EGFRGAKERBB3ERBB4 | |
| SCHEMBL4478600 | 0.89 | EGFR (0.75) | ERBB2EGFRGAKERBB3ERBB4 | |
| SCHEMBL4480888 | 0.89 | EGFR (0.63) | ERBB2EGFRGAKERBB3ERBB4 | |
| Trifluoroacetic Acid SCHEMBL3816939 | 0.88 | EGFR (0.58) | ERBB2EGFRGAKERBB3ERBB4 | |
| SCHEMBL3815062 | 0.86 | EGFR (0.70) | ERBB2EGFRGAKERBB3ERBB4 | |
| SCHEMBL3808188 | 0.85 | ERBB2 (0.80) | ERBB2EGFRKCNH2 | |
| SCHEMBL3807593 | 0.84 | EGFR (0.64) | ERBB2EGFRGAKERBB3ERBB4 | |
| SCHEMBL3807613 | 0.84 | EGFR (0.64) | ERBB2EGFRGAKERBB3ERBB4 | |
| SCHEMBL3809965 | 0.84 | EGFR (0.64) | ERBB2EGFRGAKERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631292-B1 | 4-ANILINO-QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | EP | claimed |
| US-20070149546-A1 | 4-Anilino-quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | claimed |
| EP-1631292-A1 | 4-ANILINO-QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | Astra Zeneca AB (SE) | 2006-03-08 | — | — | EP | claimed |
| WO-2004093880-A1 | 4-ANILINO-QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | claimed |
| EP-1631292-B1 | 4-ANILINO-QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | EP | disclosed |
| US-20070149546-A1 | 4-Anilino-quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| EP-1631292-A1 | 4-ANILINO-QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | Astra Zeneca AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004093880-A1 | 4-ANILINO-QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149546-A1 | 4-Anilino-quinazoline derivatives as antiproliferative agents | ABL1, ERBB2, ERBB4 | ERBB2 2/4885EGFR 10/4885GAK 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.